Built and leads Hadassah's Cancer Computational Biology Lab and AI in Oncology Unit, developing MESiCA and TP53_PROF, machine-learning models now used to interpret mutational signatures and predict the clinical impact of cancer mutations. Trained at the Technion under Karl Skorecki, Wolf Prize for excellence, and directs the Faculty of Medicine's dual MD/Computer Science programme.

Directs the Sharett Institute of Oncology, Israel's first comprehensive cancer centre, named by Newsweek among the world's leading cancer institutes. Co-author of KEYNOTE-048 (The Lancet, 2019) and other pembrolizumab trials in NEJM and The Lancet Oncology that changed the standard of care for head and neck cancer. Trained at the University of Michigan, Beth Israel Hospital, and Memorial Sloan Kettering.

Founded and directs Israel's first living organoid biobank, recently extended to organoid models of inflammatory bowel disease. Her lab's papers in Cell (2006) and Science (2021) established mechanisms now foundational to the study of blood vessel formation and vascular aging.

Chairs Hadassah's Department of Diagnostic Pathology and leads its FoundationOne molecular testing programme, one of a handful worldwide performing this level of tumour-mutation profiling. Recipient, Israel Ministry of Health prize for personalized medicine; advises industry on diagnostics and biotech.

Leads Hadassah's Computational Pathology Lab, working with UCLA's Aydogan Ozcan lab on the trust problems now central to clinical AI: in Nature Biomedical Engineering, one of the first frameworks for detecting AI hallucination in digital pathology, and in Nature Communications, virtual tissue staining that replaces chemical processing. A decade-long focus on bringing computational methods into daily clinical practice.

Directed the IDF Medical Corps' BI and Medical Data Analysis Unit for over 20 years before joining Hadassah in 2023. Co-author of over 100 peer-reviewed publications drawn from national adolescent health cohorts, including several in NEJM and JAMA. Member, Hadassah's Helsinki and Ethics Committees. Co-recipient, with Ruth Lev Bar Or and Dorit Shemesh, of the 2025 People & Computers IT Award for the oncologic DataMart.

An active research record spanning three decades: with Haim Sompolinsky (PNAS, 1995), one of the founding papers in continuous attractor network theory, and with Uri Alon and Moshe Oren (PNAS, 2000), a landmark early model in systems biology, predicting p53-Mdm2 oscillations after DNA damage later confirmed by single-cell imaging. More recently, co-author of 2025 studies on kidney function and nationwide melanoma screening. PhD in Applied Mathematics, Weizmann Institute.

Architects the platform's Read-Scale data infrastructure and its Spark/Python engineering spine, following a decade doing similar work across Israel's Ministry of Health, Clalit, and Hadassah. Works across Azure, AWS, Cloudera, and the Spark, Python, Nifi, and Airflow toolchain, and ensures compliance with national technology standards.

AI scientist leading data infrastructure and applied AI for precision oncology at Hadassah: architecture of a 275,000-patient clinical database, AI/NLP pipelines for clinical data extraction, and predictive models for treatment response and disease progression. Data scientist for the international Consortium for Liquid Biopsy, analysing multi-omics blood-sample data across a pan-cancer cohort. PhD in quantum chemistry.

Two decades as an applicative database administrator in Israel's public sector, specialising in complex query development and performance optimisation. Joined Hadassah's Data & Analytics division and, within a year, built the data warehouse now spanning roughly 1,000 tables across the hospital's systems; supports its data pipelines at the technical, logical, and application layers. Two-time recipient, Data & AI Excellence award.

Built Israel's first PET/Cyclotron facility and, in 2022, registered LuNET-SRY, the first locally-manufactured radiopharmaceutical in Israel. Directs the Hadassah Medical Organization's Research Fund: over 300 research staff and a multi-million-dollar project portfolio.

Leads Hadasit's industry partnerships across pre-clinical trials, prospective and retrospective studies, EMR integration, and regulatory support, including international accelerator programmes with IBM, drawing on her own background in law alongside an MBA in biomed. For HCIMI, will coordinate data-sharing agreements between the hospital and commercial partners.